Market capitalization | $1.24m |
Enterprise Value | $3.89m |
EV/Sales (TTM) EV/Sales | 2.29 |
P/S ratio (TTM) P/S ratio | 0.73 |
Revenue growth (TTM) Revenue growth | -21.24% |
Revenue (TTM) Revenue | $1.70m |
EBIT (operating result TTM) EBIT | $-13.95m |
Cash position | $70.00k |
EPS (TTM) EPS | $-42.12 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Jun '23 |
+/-
%
|
||
Revenue | 1.70 1.70 |
21%
21%
|
|
Gross Profit | 0.85 0.85 |
48%
48%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -14 -14 |
7%
7%
|
Net Profit | -15 -15 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.
Head office | Virgin Islands, British |
CEO | Hao Yu |
Founded | 2010 |
Website | www.anpacbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.